What is King Pharmaceuticals's goodwill?

King Pharmaceuticals (KG) reported goodwill of $8.51M in Q1 2026.

What does goodwill mean?

The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.

King Pharmaceuticals KG Goodwill

Goodwill at other companies

Arch Capital GroupACGL

$1.19B-9.0%

SiriusPointSPNT

$18.6M—

Skyward Specialty Insurance Group, Inc.SKWD

$191.14M+191%

Selective Insurance GroupSIGI

$7.85M0.0%

Verisk Analytics, Inc.VRSK

$1.86B+6.5%

W.R. BerkleyWRB

$184.33M0.0%

Segments

By segment

See full

Legacy Reinsurance$8.51M—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetIncludingGoodwill.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's goodwill?: King Pharmaceuticals (KG) reported goodwill of $8.51M in Q1 2026.
What does goodwill mean?: The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.